Browsing "Obstetrics and Gynaecology" by Title

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1671 to 1690 of 3323 < previous   next >
PreviewIssue DateTitleAuthor(s)
2020Machine learning and scoring functions (SFs) for molecular drug discovery: Prediction and characterisation of druggable drugs and targetsHudson, I.L.; Leemaqz, S.Y.; Abell, A.D.; Cartwright, H.M.
2010Macrophage activity in semen is significantly correlated with sperm quality in infertile menTremellen, K.; Tunc, O.
2004Macrophage contributions to ovarian functionWu, R.; Van Der Hoek, K.; Ryan, N.; Norman, R.; Robker, R.
2013Macrophage phenotype in the mammary gland fluctuates over the course of the estrous cycle and is regulated by ovarian steroid hormonesHodson, L.; Chua, C.; Evdokiou, A.; Robertson, S.; Ingman, W.
2011Macrophage-derived LIF and IL1B regulate alpha(1,2)fucosyltransferase 2 (Fut2) expression in mouse uterine epithelial cells during early pregnancyJasper, M.; Care, A.; Sullivan, B.; Ingman, W.; Aplin, J.; Robertson, S.
2010Macrophages are essential for maintenance of corpus luteum function in early pregnancyCare, A.S.; Jasper, M.J.; Ingman, W.V.; Robertson, S.A.; 43rd Annual Meeting of the Society for the Study of Reproduction (28 Jul 2010 - 3 Aug 2010 : Milwaukee, Wisconsin)
2006Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary glandIngman, W.; Wyckoff, J.; Gouon-Evans, V.; Condeelis, J.; Pollard, J.
2013Macrophages regulate corpus luteum development during embryo implantation in miceCare, A.; Diener, K.; Jasper, M.; Brown, H.; Ingman, W.; Robertson, S.
2012Macrophages regulate expression of α1,2-fucosyltransferase genes in human endometrial epithelial cellsNakamura, H.; Jasper, M.; Hull, M.; Aplin, J.; Robertson, S.
2015Macrosomic and low birth weight neonates in Pacific Islanders from Samoa: a case-control studyTsitas, M.; Schmid, B.; Oehler, M.; Tempfer, C.
2000Magnesium for preventing preterm birth after threatened preterm labourCrowther, C.; Moore, V.; Crowther, C.A.
2013Magnesium maintenance therapy for preventing preterm birth after threatened preterm labourHan, S.; Crowther, C.; Moore, V.
1998Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour (Review)Han, S.; Crowther, C.; Moore, V.; Crowther, C.A.
2004Magnesium sulfate for preterm neuroprotection - ReplyCrowther, C.; Hiller, J.; Doyle, L.; Haslam, R.
2013Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA) -study protocolCrowther, C.; Middleton, P.; Wilkinson, D.; Ashwood, P.; Haslam, R.
2014Magnesium sulphate for preventing preterm birth in threatened preterm labourCrowther, C.; Brown, J.; McKinlay, C.; Middleton, P.
2000Magnesium sulphate for preventing preterm birth in threatened preterm labour [protocol]Crowther, C.; Hiller, J.; Doyle, L.; Crowther, C.A.
2007Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetusDoyle, L.; Crowther, C.; Middleton, P.; Marret, S.; Rouse, D.; Doyle, L.W.
2009Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetusDoyle, L.; Crowther, C.; Middleton, P.; Marret, S.; Rouse, D.
2013Magnesium sulphate for women at term for neuroprotection of the fetusNguyen, T.; Crowther, C.; Wilkinson, D.; Bain, E.